Bristol Myers - International Biopharmaceutical Industry

Current Edition

news

Nektar, Bristol Myers drug combination fails in late-stage melanoma trial

Dive Brief: Shares in Nektar Therapeutics fell by more than half Monday morning after the San Francisco biotech company and partner Bristol Myers Squibb disclosed ...

21 March 2022 news Biotech | Bristol Myers

Continue Reading →

news

Bristol Myers returns to Immatics for a dual-targeting cancer drug

Bristol Myers' acquisition of Celgene immediately made the big pharma a top player in the development of cancer cell therapies. Since the deal closed, Bristol Myers h...

15 December 2021 news Breyanzi | Bristol Myers

Continue Reading →

news

Bristol Myers’ top autoimmune drug prospect takes a hit in mid-stage trial

Deucravacitinib is important to Bristol Myers for several reasons. The drug is seen as a potential top-seller, leading a new class of oral drugs that could challenge...

8 October 2021 news anti-inflammatory medicine | autoimmune

Continue Reading →

International Biopharmaceutical Industry

IBI – International Biopharmaceutical Industry was established to fill in the void for effective marketing and communication between all stakeholders in the Life sciences sector globally.

Current Edition

Upcoming Events

Advertisement

Nektar, Bristol Myers drug combination fails in late-stage melanoma trial

Bristol Myers returns to Immatics for a dual-targeting cancer drug

Bristol Myers’ top autoimmune drug prospect takes a hit in mid-stage trial

International Biopharmaceutical Industry